Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bitopertin in Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
NCT06910358Phase 3Completed
- Sponsor
- Disc Medicine
- Start
- Apr 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of bitopertin in erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), sponsored by Disc Medicine. Started Apr 2025; status: completed.
02
Drugs
bitopertin
03
Conditions
erythropoietic protoporphyria (EPP)X-linked protoporphyria (XLP)
Beyond the preview
Go deeper on NCT06910358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06910358.